CD274 and neoplasm: There have been several subsequent approvals of PD-L1 immunohistochemical assays, and PD-1 targeting drugs, leading to some efforts to establish a concordance [11], and Dr Rubin noted multiple assays are currently being developed to evaluate tumour mutational burden.